Literature DB >> 16033818

Measurement of matrix metalloproteinases in serum of patients with melanoma: snarled in technical pitfalls.

Stanley Zucker1, Jian Cao.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16033818     DOI： 10.1158/1078-0432.CCR-05-0774

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  11 in total

Review 1.  Matrix metalloproteinases and tissue inhibitors of metalloproteinases in chronic kidney disease and acute kidney injury: a systematic review of the literature.

Authors:  C L Sampieri; R A Orozco-Ortega
Journal:  Hippokratia       Date:  2018 Jul-Sep       Impact factor: 0.471

2.  Comparison of localized versus systemic levels of Matrix metalloproteinases (MMPs), its tissue inhibitors (TIMPs) and cytokines in tuberculous and non-tuberculous pleuritis patients.

Authors:  Swetha Sundararajan; Subash Babu; Sulochana D Das
Journal:  Hum Immunol       Date:  2012-07-20       Impact factor: 2.850

3.  Longitudinal prospective study of matrix metalloproteinase-9 as a serum marker in gliomas.

Authors:  Fabio M Iwamoto; Andreas F Hottinger; Sasan Karimi; Elyn Riedel; Jocelynn Dantis; Maryam Jahdi; Katherine S Panageas; Andrew B Lassman; Lauren E Abrey; Martin Fleisher; Lisa M Deangelis; Eric C Holland; Adília Hormigo
Journal:  J Neurooncol       Date:  2011-06-28       Impact factor: 4.130

Review 4.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Authors:  Roopali Roy; Jiang Yang; Marsha A Moses
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

Review 5.  Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the tumors of central nervous system (CNS).

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Johannes Kornhuber; Piotr Lewczuk
Journal:  J Neural Transm (Vienna)       Date:  2013-12-24       Impact factor: 3.575

6.  Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles.

Authors:  Klaus Jung; Ferdinando Mannello; Michael Lein
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

7.  Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.

Authors:  N El Houda Agueznay; C Badoual; S Hans; A Gey; B Vingert; S Peyrard; F Quintin-Colonna; P Ravel; P Bruneval; S Roncelin; B Lelongt; J Bertoglio; W H Fridman; D Brasnu; E Tartour
Journal:  Clin Exp Immunol       Date:  2007-08-03       Impact factor: 4.330

8.  Liquid biopsies in patients with diffuse glioma.

Authors:  Myron G Best; Nik Sol; Sebastiaan Zijl; Jaap C Reijneveld; Pieter Wesseling; Thomas Wurdinger
Journal:  Acta Neuropathol       Date:  2015-02-27       Impact factor: 17.088

9.  Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy.

Authors:  K Jung
Journal:  Br J Cancer       Date:  2008-07-22       Impact factor: 7.640

10.  Levels of matrix metalloproteinases differ in plasma and serum - aspects regarding analysis of biological markers in cancer.

Authors:  Andreas Jonsson; Claes Hjalmarsson; Peter Falk; Marie-Lois Ivarsson
Journal:  Br J Cancer       Date:  2016-05-17       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.